383 related articles for article (PubMed ID: 22531234)
41. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
42. [Respiratory syncytial virus prophylaxis among preterm infants--four seasons' experience].
Klimek M; Kwinta P; Kruczek P; Pietrzyk JJ
Przegl Lek; 2009; 66(1-2):34-8. PubMed ID: 19485253
[TBL] [Abstract][Full Text] [Related]
43. [Palivizumab immunoprophylaxis: use in clinical practice, safety and beneficial effects in France].
Pinquier D; Gouyon JB; Fauroux B; Mons F; Vicaut E; Bendjenana H; Rouffiac E; Marret S; Aujard Y
Arch Pediatr; 2009 Nov; 16(11):1443-52. PubMed ID: 19767182
[TBL] [Abstract][Full Text] [Related]
44. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
45. Palivizumab use in very premature infants in the neonatal intensive care unit.
Wu SY; Bonaparte J; Pyati S
Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
[TBL] [Abstract][Full Text] [Related]
46. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
47. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
Cox RA; Rao P; Brandon-Cox C
J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
[TBL] [Abstract][Full Text] [Related]
48. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
Grupo de Hospitales Benazuza
An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
[TBL] [Abstract][Full Text] [Related]
49. Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins.
Dotan M; Ashkenazi-Hoffnung L; Samra Z; Livni G; Yarden-Bilavsky H; Amir J; Bilavsky E
Isr Med Assoc J; 2013 Nov; 15(11):701-4. PubMed ID: 24511652
[TBL] [Abstract][Full Text] [Related]
50. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
51. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
Pediatrics; 1998 Sep; 102(3):531-7. PubMed ID: 9724660
[TBL] [Abstract][Full Text] [Related]
52. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I; Tough S; Gillis L; Majaesic C
Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
[TBL] [Abstract][Full Text] [Related]
53. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
54. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age.
Stensballe LG; Fullarton JR; Carbonell-Estrany X; Simões EA
Pediatr Infect Dis J; 2010 Apr; 29(4):374-6. PubMed ID: 20016397
[TBL] [Abstract][Full Text] [Related]
55. [Usefulness of different risk factor associations in predicting admissions due to respiratory syncytial virus in premature newborns of 32 to 35 weeks gestation in Spain].
Figueras-Aloy J; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
An Pediatr (Barc); 2009 Jul; 71(1):47-53. PubMed ID: 19524492
[TBL] [Abstract][Full Text] [Related]
56. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)].
Figueras Aloy J; Carbonell Estrany X;
An Pediatr (Barc); 2010 Aug; 73(2):98.e1-4. PubMed ID: 20621574
[TBL] [Abstract][Full Text] [Related]
57. Effects of parental and household smoking on the risk of respiratory syncytial virus (RSV) hospitalisation in late-preterm infants and the potential impact of RSV prophylaxis.
Carbonell-Estrany X; Fullarton JR; Gooch KL; Vo PG; Figueras-Aloy J; Lanari M; Gouyon JB; Liese JG
J Matern Fetal Neonatal Med; 2013 Jun; 26(9):926-31. PubMed ID: 23379728
[TBL] [Abstract][Full Text] [Related]
58. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
[TBL] [Abstract][Full Text] [Related]
59. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
60. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
